SNMMI 65th Annual Meeting sets the stage for a revolution in precision medicine

June 28, 2018

RESTON, VA - More than 5,000 physicians, technologists, scientists and exhibitors gathered for the Society of Nuclear Medicine and Molecular Imaging's 65th Annual Meeting, held June 23-26 in Philadelphia.

The meeting had more than 850 scientific oral presentations and nearly 1,000 posters, as well as sessions on new tracers and applications, emerging technologies, updates on appropriate use criteria and coding and reimbursement, Mo-99 production and availability, and new "Nuts and Bolts" sessions in each track that covered a wide variety of subspecialty areas, providing practical information to apply in the clinic. The CT and MRI Case Reviews, always a draw, were presented in collaboration with the University of Pennsylvania.

With nuclear medicine playing a growing role in providing precision medicine, theranostics (combining diagnostic imaging and targeted radionuclide therapy) were an important focus throughout the meeting.

The Saturday evening Opening Ceremony provided an overview of the meeting and introduced China as the Highlight Country. Chinese drummers and dragons then led the way to the Welcome Reception and Exhibit Hall Opening. The Chinese society organized scientific and CE sessions throughout the meeting.

The Sunday plenary session featured the Henry N. Wagner, MD, Lecture on Quantitative Nuclear Imaging: Is SUV the Best We Can Do? given by Richard E. Carson, PhD, professor of radiology, biomedical imaging and biomedical engineering at Yale University; director of the Yale PET Center; and director of graduate studies for Yale's biomedical engineering program. His presentation covered tracer kinetic analysis methods used for quantitative brain imaging applications, with a focus on synaptic density imaging, why SUV works as well as it does for FDG oncology studies, and imaging challenges faced in non-brain dynamic studies. Carson claimed that we can do better, and more research is needed to determine the best timing and to optimize methods.

The Sunday plenary also included an update on SNMMI's Value Initiative, which addresses five critical domains that will guide the society's strategic plan over the next several years: Quality of Practice, Research and Development, Workforce Pipeline Life-Long Learning, Advocacy, and Outreach.

Simon R. Cherry, PhD, Distinguished Professor at the University of California, Davis, was named the 2018 recipient of the prestigious Paul C. Aebersold Award for outstanding achievement in basic nuclear medicine. His major accomplishments have been in developing and applying high-resolution systems for positron emission tomography (PET), particularly the invention of microPET technology, and co-leading the EXPLORER project which recently has built the world's first total-body PET scanner.

Richard L. Wahl, MD, FACNM, FACR, received the Georg Charles de Hevesy Nuclear Pioneer Award for his contributions to nuclear medicine. Wahl is the Elizabeth E. Mallinckrodt Professor and head of radiology at Washington University School of Medicine in St. Louis, director of the university's Mallinckrodt Institute of Radiology and a professor of radiation oncology. His research played an important role in the development of radioimmunotherapy for non-Hodgkin's lymphoma. He has also been a pioneer in the use of PET scans to diagnose and assess treatment of a broad array of human cancers and other diseases.

At the Monday plenary session, Sanjiv Sam Gambhir, MD, PhD, presented the Cassen Lectureship on Multimodality Molecular Imaging of Cell/Gene Therapies for Early Disease Detection and Management. Gambhir is the Virginia and D.K. Ludwig Professor of Cancer Research and the chair of the Department of Radiology at the Stanford University School of Medicine. He also heads up the Canary Center at Stanford for Cancer Early Detection and directs the Molecular Imaging Program at Stanford (MIPS). Gambhir outlined research on delivering reporter genes, which can correct genetic errors--forcing a gene to make a useful protein that can also be imaged and tracked. In addition, he discussed CAR-T therapy (short for chimeric antigen receptor T-cell therapy), in which CAR-T cells bind to an antigen on cancer cells and kill them. Gambhir predicted, "A revolution in precision health is coming."

The 2018 Image of the Year went to a team of researchers at the Peter MacCallum Cancer Centre in Melbourne, Australia. The image, using gallium-68 (68Ga)-PSMA11 PET imaging, demonstrates exceptional responses in a series of patients with advanced prostate cancer who received LuPSMA therapy after other treatments stopped working. In each patient, the extent of tumor spread before and after treatment is visualized with clarity using PSMA PET. These patients experienced improved quality of life, including reduction of pain, and correlated with marked reduction of prostate specific antigen (PSA), a blood tumor marker.

With the focus always on patients, Patient Education Day is an important part of the annual meeting. Patients and caregivers attended sessions on nuclear medicine advances in diagnosing and treating neuroendocrine tumors, prostate and lymphoma.

The Exhibit Hall provided a one-stop showcase for cutting-edge molecular imaging devices, products, and services. New this year, Interactive Training Showcases in the Hall featured 30-minute training sessions on the use of new technologies and equipment by major exhibitors.

SNMMI TV again provided daily coverage of meeting highlights and interviews on topics ranging from theranostics and the Clinical Trials Network to patient advocacy and molecular imaging applications. In addition to showings throughout the meeting, the videos are available on the SNMMI YouTube site.

SNMMI is offering a Virtual Meeting for those who were unable to attend certain sessions or make the trip to Philadelphia. A Virtual Poster hall will also be offered. The SNMMI 2019 Annual Meeting will take place June 22-25 in Anaheim, California.
-end-
ABOUT THE SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

The Society of Nuclear Medicine and Molecular Imaging (SNMMI) is an international scientific and medical organization dedicated to advancing nuclear medicine and molecular imaging, a vital element of today's medical practice that adds an additional dimension to diagnosis, changing the way common and devastating diseases are understood and treated and helping provide patients with the best health care possible.

SNMMI's more than 16,000 members set the standard for molecular imaging and nuclear medicine practice by creating guidelines, sharing information through journals and meetings and leading advocacy on key issues that affect molecular imaging and therapy research and practice. For more information, visit http://www.snmmi.org.

Society of Nuclear Medicine and Molecular Imaging

Related Cancer Cells Articles from Brightsurf:

Cancer researchers train white blood cells to attacks tumor cells
Scientists at the National Center for Tumor Diseases Dresden (NCT/UCC) and Dresden University Medicine, together with an international team of researchers, were able to demonstrate that certain white blood cells, so-called neutrophil granulocytes, can potentially - after completing a special training program -- be utilized for the treatment of tumors.

New way to target some rapidly dividing cancer cells, leaving healthy cells unharmed
Scientists at Johns Hopkins Medicine and the University of Oxford say they have found a new way to kill some multiplying human breast cancer cells by selectively attacking the core of their cell division machinery.

Breast cancer cells use message-carrying vesicles to send oncogenic stimuli to normal cells
According to a Wistar study, breast cancer cells starved for oxygen send out messages that induce oncogenic changes in surrounding normal epithelial cells.

Breast cancer cells turn killer immune cells into allies
Researchers at Johns Hopkins University School of Medicine have discovered that breast cancer cells can alter the function of immune cells known as Natural killer (NK) cells so that instead of killing the cancer cells, they facilitate their spread to other parts of the body.

Breast cancer cells can reprogram immune cells to assist in metastasis
Johns Hopkins Kimmel Cancer Center investigators report they have uncovered a new mechanism by which invasive breast cancer cells evade the immune system to metastasize, or spread, to other areas of the body.

Engineered immune cells recognize, attack human and mouse solid-tumor cancer cells
CAR-T therapy has been used successfully in patients with blood cancers such as lymphoma and leukemia.

Drug that keeps surface receptors on cancer cells makes them more visible to immune cells
A drug that is already clinically available for the treatment of nausea and psychosis, called prochlorperazine (PCZ), inhibits the internalization of receptors on the surface of tumor cells, thereby increasing the ability of anticancer antibodies to bind to the receptors and mount more effective immune responses.

Engineered bone marrow cells slow growth of prostate and pancreatic cancer cells
In experiments with mice, researchers at the Johns Hopkins Kimmel Cancer Center say they have slowed the growth of transplanted human prostate and pancreatic cancer cells by introducing bone marrow cells with a specific gene deletion to induce a novel immune response.

First phase i clinical trial of CRISPR-edited cells for cancer shows cells safe and durable
Following the first US test of CRISPR gene editing in patients with advanced cancer, researchers report these patients experienced no negative side effects and that the engineered T cells persisted in their bodies -- for months.

Zika virus' key into brain cells ID'd, leveraged to block infection and kill cancer cells
Two different UC San Diego research teams identified the same molecule -- αvβ5 integrin -- as Zika virus' key to brain cell entry.

Read More: Cancer Cells News and Cancer Cells Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.